Medigen Vaccine Biologics Corp (高端疫苗) would cooperate with the US National Institutes of Health to develop a vaccine against COVID-19, the company said yesterday, adding that it plans to begin animal testing in the second quarter of this year.
The Hsinchu-based company on Sunday signed an agreement with the US agency, which is to provide a vaccine candidate and the viral spike protein to Medigen for testing and development, spokesman Leo Lee (李思賢) told a news conference in Taipei.
Medigen Vaccine would use recombinant spike protein technology to develop the vaccine, Lee said.
Photo: Kao Shih-ching, Taipei Times
The agency last month partnered with US-based Moderna Inc to develop a vaccine utilizing messenger RNA technology.
Medigen Vaccine would inject the spike protein-based vaccine candidate into rats to observe their immunogenicity and examine whether the vaccine prototype is safe, Lee said.
While animal testing for vaccine development normally takes four to six months, the firm plans to finish the tests before the end of June to speed up the process, he added.
It then plans to apply to the Food and Drug Administration (FDA) to run a double-blind clinical test in the second half of this year, concentrating on the vaccines’ efficacy and safety, he added.
The company would not conduct human trials on infected people, but on healthy volunteers, vice chairman Charles Chen (陳燦堅) said.
“It will not be accurate to run preliminary tests on infected people. As patients’ immune systems would create antibodies, we would not know whether their recovery is attributable to their own antibodies or the vaccine’s,” Chen said.
The number of volunteers and the duration of the tests would be determined by FDA regulations, he said.
“The government might allow us to speed up the process and recruit fewer volunteers, but we expect to at least complete phase one tests or combine phase one and two tests to save time,” Chen said.
If the vaccine is proven effective, Medigen Vaccine expects to manufacture and sell it in Taiwan and neighboring countries, Chen added.
Chen, who discussed the cooperation with the US agency before the Lunar New Year holiday, said the two sides have been producing dengue vaccines since 2016.
Compared with the regular development of vaccines, the research and development costs for a vaccine against COVID-19 would be much lower due to the US agency’s resources, Medigen Vaccine financial director Jade Yang (楊郁萍) said.
Shares of Medigen Vaccine jumped 9.97 percent to close at NT$35.85 in Taipei trading yesterday.
Semiconductor shares in China surged yesterday after Reuters reported the US had ordered chipmaking giant Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to halt shipments of advanced chips to Chinese customers, which investors believe could accelerate Beijing’s self-reliance efforts. TSMC yesterday started to suspend shipments of certain sophisticated chips to some Chinese clients after receiving a letter from the US Department of Commerce imposing export restrictions on those products, Reuters reported on Sunday, citing an unnamed source. The US imposed export restrictions on TSMC’s 7-nanometer or more advanced designs, Reuters reported. Investors figured that would encourage authorities to support China’s industry and bought shares
FLEXIBLE: Taiwan can develop its own ground station equipment, and has highly competitive manufacturers and suppliers with diversified production, the MOEA said The Ministry of Economic Affairs (MOEA) yesterday disputed reports that suppliers to US-based Space Exploration Technologies Corp (SpaceX) had been asked to move production out of Taiwan. Reuters had reported on Tuesday last week that Elon Musk-owned SpaceX had asked their manufacturers to produce outside of Taiwan given geopolitical risks and that at least one Taiwanese supplier had been pushed to relocate production to Vietnam. SpaceX’s requests place a renewed focus on the contentious relationship Musk has had with Taiwan, especially after he said last year that Taiwan is an “integral part” of China, sparking sharp criticism from Taiwanese authorities. The ministry said
US President Joe Biden’s administration is racing to complete CHIPS and Science Act agreements with companies such as Intel Corp and Samsung Electronics Co, aiming to shore up one of its signature initiatives before US president-elect Donald Trump enters the White House. The US Department of Commerce has allocated more than 90 percent of the US$39 billion in grants under the act, a landmark law enacted in 2022 designed to rebuild the domestic chip industry. However, the agency has only announced one binding agreement so far. The next two months would prove critical for more than 20 companies still in the process
CHANGING JAPAN: Nvidia-powered AI services over cellular networks ‘will result in an artificial intelligence grid that runs across Japan,’ Nvidia’s Jensen Huang said Softbank Group Corp would be the first to build a supercomputer with chips using Nvidia Corp’s new Blackwell design, a demonstration of the Japanese company’s ambitions to catch up on artificial intelligence (AI). The group’s telecom unit, Softbank Corp, plans to build Japan’s most powerful AI supercomputer to support local services, it said. That computer would be based on Nvidia’s DGX B200 product, which combines computer processors with so-called AI accelerator chips. A follow-up effort will feature Grace Blackwell, a more advanced version, the company said. The announcement indicates that Softbank Group, which until early 2019 owned 4.9 percent of Nvidia, has secured a
RSS